Drug
Bimagrumab clinical trials
Also written BYM338 and LY3985863.
- studies test it
- 17
- open now
- 1
- in phase 3
- 3
- first study started
- 2011
Keep track of what changes. Save the bimagrumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
17 studies that test it; most in 2014 (4)
| Year | Studies |
|---|---|
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 4 |
| 2015 | 2 |
| 2017 | 1 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 15
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 16 · Other 1
Novartis Pharmaceuticals (12) · Eli Lilly and Company (4) · Massachusetts General Hospital (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses bimagrumab is read from its arms, and is right about nine times in ten.
Testing it · 17
- Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With ObesityRecruitingPhase 2Massachusetts General HospitalNCT05933499Written as Bimagrumab
- Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or ObeseCompletedPhase 2Eli Lilly and CompanyNCT05616013Written as Bimagrumab
- A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or OverweightActive, not recruitingPhase 2Eli Lilly and CompanyNCT06643728Written as Bimagrumab
- A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT06890611Written as Bimagrumab
- A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 DiabetesWithdrawnPhase 2Eli Lilly and CompanyNCT06901349Written as Bimagrumab
- Dose Range Finding Study of Bimagrumab in SarcopeniaCompletedPhase 2Novartis PharmaceuticalsNCT02333331Written as bimagrumab
- Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 DiabetesCompletedPhase 2Novartis PharmaceuticalsNCT03005288Written as BYM338 10 mg/kg
- Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body MyositisCompletedPhase 2/3Novartis PharmaceuticalsNCT02250443Written as BYM338 (Bimagrumab)
- Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body MyositisCompletedPhase 2Novartis PharmaceuticalsNCT01423110Written as BYM338
- A Multi-center Study to Assess the Effects of BYM338 on Skeletal Muscle in Sarcopenic AdultsCompletedPhase 2Novartis PharmaceuticalsNCT01601600Written as BYM338
- Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture SurgeryCompletedPhase 2Novartis PharmaceuticalsNCT02152761Written as bimagrumab
- A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core StudyCompletedPhase 2Novartis PharmaceuticalsNCT02468674Written as bimagrumab
- An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203CompletedPhase 3Novartis PharmaceuticalsNCT02573467Written as Bimagrumab
- Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM PatientsCompletedPhase 2/3Novartis PharmaceuticalsNCT01925209Written as BYM338/bimagrumab
- BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With CachexiaCompletedPhase 2Novartis PharmaceuticalsNCT01669174Written as BYM338
- Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the PancreasCompletedPhase 2Novartis PharmaceuticalsNCT01433263Written as BYM338 active drug
- Study of Muscle Effects of BYM338 in Mechanically Ventilated PatientsWithdrawnPhase 2Novartis PharmaceuticalsNCT01868685Written as BYM338
Codes
What other systems call bimagrumab · ClinicalTrials.gg INT000196
- MeSH (NLM) C000596367bimagrumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) N15SW1DIV8BIMAGRUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q15708291bimagrumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C116852BimagrumabOne source FDA
- DrugBank DB12584One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000596367 | bimagrumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | N15SW1DIV8 | BIMAGRUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q15708291 | bimagrumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C116852 | Bimagrumab | One source FDA |
| DrugBank | DB12584 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.